Cargando…
Effect of bevacizumab against cystic components of brain tumors
BACKGROUND: Bevacizumab improves symptoms via reducing the peritumoral edema and/or normalizing blood brain barrier, and occasionally via reducing the tumor size. However, the effect against active cystic components has not been documented yet. MATERIALS AND METHODS: Between 2008 and 2018, 139 patie...
Autores principales: | Yamasaki, Fumiyuki, Kolakshyapati, Manish, Takano, Motoki, Yonezawa, Ushio, Nishibuchi, Ikuno, Imano, Nobuki, Taguchi, Akira, Onishi, Shumpei, Amatya, Vishwa Jeet, Takeshima, Yukio, Nagata, Yasushi, Kurisu, Kaoru, Sugiyama, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825995/ https://www.ncbi.nlm.nih.gov/pubmed/31498567 http://dx.doi.org/10.1002/cam4.2537 |
Ejemplares similares
-
COT-17 EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019) -
NI-17 T2-FLAIR MISMATCH SIGN IN DIFFUSE GLIOMA AND DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR
por: Onishi, Shumpei, et al.
Publicado: (2019) -
Epstein-barr Virus Negative Primary Central Nervous System Lymphoma Developed after Treatment of Glioblastoma: A Case Report
por: KHAIRUNNISA, Novita Ikbar, et al.
Publicado: (2022) -
COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2020) -
Metachronous Double Pituitary Adenoma with Altered Transcriptional Factor Profile: A Case Report and Literature Review
por: TAGUCHI, Akira, et al.
Publicado: (2021)